Multifactorial basis for coronary collateralization: A complex adaptive response to ischemia

Cardiovascular Research

Volumn 43, Issue 1, 1999, Pages 44-57

  Kersten, Judy R ^a   Pagel, Paul S ^a   Chilian, William M ^a   Warltier, David C ^a  

^a Pharmacol Toxicol Physiol M   (United States)

Author keywords

Angiogenesis; Coronary collateral; Growth factors; Myocardial ischemia; Vasculogenesis

Indexed keywords

FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; NITRIC OXIDE; SOMATOMEDIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; SHEAR STRESS;

ANIMALS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; GROWTH SUBSTANCES; HUMANS; MYOCARDIAL ISCHEMIA; NITRIC OXIDE; RATS; RECEPTORS, GROWTH FACTOR;

EID: 0033001169     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00077-2     Document Type: Review

References (149)

1. Schaper W., Schaper J. Collateral Circulation: Heart, Brain, Kidney, Limbs. 1993;Kluwer, Boston.
2. Kersten J.R., Pagel P.S., Warltier D.C. Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion. Am J Physiol. 268:1995;H720-728.
3. Franklin D., McKown D., McKown M., Harley J., Caldwell M. Development and regression of coronary collaterals induced by repeated, reversible ischemia in dogs [abstract]. Fed Proc. 40:1981;339.
4. Schaper W., Sharma H.S., Quinkler W., Markert T., Wunsch M., Schaper J. Molecular biologic concepts of coronary anastomoses. J Am Coll Cardiol. 15:1990;513-518.
5. Scheel K.W., Williams S.E. Hypertrophy and coronary and collateral vascularity in dogs with severe chronic anemia. Am J Physiol. 249:1985;H1031-1037.
6. Meininger C.J., Schelling M.E., Granger H.J. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am J Physiol. 255:1988;H554-562.
7. Schaper W. Angiogenesis in the adult heart. Basic Res Cardiol. 86:(Suppl 2):1991;51-56.
8. Mall G., Schikora I., Mattfeldt T., Bodle R. Dipyridamole-induced neoformation of capillaries in the rat heart. Quantitative stereological study on papillary muscles. Lab Invest. 57:1987;86-93.
9. Mattfeldt T., Mall G. Dipyridamole-induced capillary endothelial cell proliferation in the rat heart - a morphometric investigation. Cardiovasc Res. 17:1983;229-237.
10. Ziada A.M., Hudlicka O., Tyler K.R., Wright A.J. The effect of long-term vasodilatation on capillary growth and performance in rabbit heart and skeletal muscle. Cardiovasc Res. 18:1984;724-732.
11. Waxman A.M. Blood vessel growth as a problem in morphogenesis: a physical theory. Microvasc Res. 22:1981;32-42.
12. Folkman J. Angiogenesis. Jaffe E.A. Biology of Endothelial Cells. 1984;Martinus Nijhoff, Boston.
13. Madri J.A., Dreyer B., Pitlick F.A., Furthmayr H. The collagenous components of the subendothelium. Correlation of structure and function. Lab Invest. 43:1980;303-315.
14. Gross J.L., Moscatelli D., Rifkin D.B. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sci USA. 80:1983;2623-2627.
15. Ausprunk D.H., Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 14:1977;53-65.
16. Joseph-Silverstein J., Rifkin D.B. Endothelial cell growth factors and the vessel wall. Semin Thromb Hemost. 13:1987;504-513.
17. Folkman J. Tumor angiogenesis. Adv Cancer Res. 43:1985;175-203.
18. Kass R.W., Kotler M.N., Yazdanfar S. Stimulation of coronary collateral growth: Current developments in angiogenesis and future clinical applications. Am Heart J. 123:1992;486-496.
19. Folkman J., Haudenschild C. Angiogenesis in vitro. Nature. 288:1980;551-556.
20. Schaper W. Collateral vessel growth in the human heart. Role of fibroblast growth factor-2. Circulation. 94:1996;600-601.
21. Schaper W. New paradigms for collateral vessel growth. Basic Res Cardiol. 88:1993;193-198.
22. Schaper W., Gorge G., Winkler B., Schaper J. The collateral circulation of the heart. Prog Cardiovasc Dis. 31:1988;57-77.
23. Ware J.A., Simons M. Angiogenesis in ischemic heart disease. Nature Med. 3:1997;158-164.
24. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
25. Schaper W., De Brabander M., Lewi P. DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res. 28:1971;671-679.
26. Pasyk S., Schaper W., Schaper J., Pasyk K., Miskiewicz G., Steinseifer B. DNA synthesis in coronary collaterals after coronary artery occlusion in conscious dog. Am J Physiol. 242:1982;H1031-1037.
27. Fujita M., Sasayama S., Ohno A., Yamanishi K., Araie E., Franklin D. Importance of myocardial ischemia for coronary collateral development in conscious dogs. Int J Cardiol. 27:1990;179-186.
28. Mohri M., Tomoike H., Noma M., Inoue T., Hisano K., Nakamura M. Duration of ischemia is vital for collateral development: repeated brief coronary artery occlusions in conscious dogs. Circ Res. 64:1989;287-296.
29. Yamanishi K., Fujita M., Ohno A., Sasayama S. Importance of myocardial ischaemia for recruitment of coronary collateral circulation in dogs. Cardiovasc Res. 24:1990;271-277.
30. Chilian W.M., Mass H.J., Williams S.E., Layne S.M., Smith E.E., Scheel K.W. Microvascular occlusions promote coronary collateral growth. Am J Physiol. 258:1990;H1103-1111.
31. Scheel K.W., Rodriguez R.J., Ingram L.A. Directional coronary collateral growth with chronic circumflex occlusion in the dog. Circ Res. 40:1977;384-390.
32. Kumar S., West D., Shahabuddin S., et al. Angiogenesis factor from human myocardial infarcts. Lancet. 2:1983;364-368.
33. Stavri G.T., Zachary I.C., Baskerville P.A., Martin J.F., Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxi. Circulation. 92:1995;11-14.
34. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 270:1995;13333-13340.
35. Resnick N., Collins T., Atkinson W., Bonthron D.T., Dewey C.F. Jr., Gimbrone M.A. Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci USA. 90:1993;4591-4595.
36. Venema R.C., Nishida K., Alexander R.W., Harrison D.G., Murphy T.J. Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochim Biophys Acta. 1218:1994;413-420.
37. Schaper W. The Pathophysiology of myocardial perfusion. 1979;Elsevier, New York.
38. Casscells W., Speir E., Sasse J., et al. Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest. 85:1990;433-441.
39. Schott R.J., Morrow L.A. Growth factors and angiogenesis. Cardiovasc Res. 27:1993;1155-1161.
40. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev. 8:1987;95-114.
41. Mignatti P., Morimoto T., Rifkin D.B. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sci USA. 88:1991;11007-11011.
42. Sato Y., Rifkin D.B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol. 107:1988;1199-1205.
43. Montesano R., Vassalli J.D., Baird A., Guillemin R., Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA. 83:1986;7297-7301.
44. Speir E., Tanner V., Gonzalez A.M., Farris J., Baird A., Casscells W. Acidic and basic fibroblast growth factors in adult rat heart myocytes. Localization, regulation in culture, and effects on DNA synthesis. Circ Res. 71:1992;251-259.
45. Sasaki H., Hoshi H., Hong Y.M., et al. Purification of acidic fibroblast growth factor from bovine heart and its localization in the cardiac myocytes. J Biol Chem. 264:1989;17606-17612.
46. Bernotat-Danielowski S., Sharma H.S., Schott R.J., Schaper W. Generation and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic collateralised porcine myocardium. Cardiovasc Res. 27:1993;1220-1228.
47. Cohen M.V., Vernon J., Yaghdjian V., Hatcher V.B. Longitudinal changes in myocardial basic fibroblast growth factor (FGF-2) activity following coronary artery ligation in the dog. J Mol Cell Cardiol. 26:1994;683-690.
48. Fujita M., Ikemoto M., Kishishita M., et al. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation. 94:1996;610-613.
49. Hasdai D., Barak V., Leibovitz E., et al. Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int J Cardiol. 59:1997;133-138.
50. Cuevas P., Barrios V., Gimenez-Gallego G., et al. Serum levels of basic fibroblast growth factor in acute myocardial infarction. Eur J Med Res. 2:1997;282-284.
51. Gajdusek C.M., Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol. 139:1989;570-579.
52. Hashimoto E., Ogita T., Nakaoka T., Matsuoka R., Takao A., Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol. 267:1994;H1948-1954.
53. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
54. Ferrara N., Houck K.A., Jakeman L.B., Winer J., Leung D.W. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 47:1991;211-218.
55. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 266:1991;11947-11954.
56. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocr. 5:1991;1806-1814.
57. Paavonen K., Horelli-Kuitunen N., Chilov D., et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation. 93:1996;1079-1082.
58. Olofsson B., Pajusola K., Kaipainen A., et al. Vascular endothelial growth factor B., a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 93:1996;2576-2581.
59. Witzenbichler B., Asahara T., Murohara T., et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 153:1998;381-394.
60. Shinohara K., Shinohara T., Mochizuki N., et al. Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels. 11:1996;113-122.
61. Banai S., Shweiki D., Pinson A., Chandra M., Lazarovici G., Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 28:1994;1176-1179.
62. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 90:1994;649-652.
63. Levy A.P., Levy N.S., Loscalzo J., et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res. 76:1995;758-766.
64. Stein I., Neeman M., Shweiki D., Itin A., Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol. 15:1995;5363-5368.
65. Ladoux A., Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun. 195:1993;1005-1010.
66. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
67. Gu J.W., Adair T.H. Hypoxia-induced expression of VEGF is reversible in myocardial vascular smooth muscle cells. Am J Physiol. 273:1997;H628-633.
68. Goldberg M.A., Gaut C.C., Bunn H.F. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood. 77:1991;271-277.
69. 2 tension. Proc Natl Acad Sci USA. 92:1995;5510-5514.
70. Goldberg M.A., Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem. 269:1994;4355-4359.
71. Goldberg M.A., Dunning S.P., Bunn H.F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 242:1988;1412-1415.
72. Rondon I.J., MacMillan L.A., Beckman B.S., et al. Hypoxia up-regulates the activity of a novel erythropoietin mRNA binding protein. J Biol Chem. 266:1991;16594-16598.
73. Ikeda E., Achen M.G., Breier G., Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 270:1995;19761-19766.
74. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 271:1996;2746-2753.
75. Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem. 273:1998;6417-6423.
76. Pepper M.S., Vassalli J.D., Orci L., Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res. 204:1993;356-363.
77. Stavri G.T., Hong Y., Zachary I.C., et al. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 358:1995;311-315.
78. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 69:1993;508-517.
79. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 189:1992;824-831.
80. Weihrauch D., Tessmer J., Warltier D.C., Chilian W.M. Repetitive coronary artery occlusions induce release of growth factors into the myocardial interstitium. Am J Physiol. 275:1998;H969-H976.
81. Kersten J.R., McGough M.F., Pagel P.S., Tessmer J.P., Warltier D.C. Temporal dependence of coronary collateral development. Cardiovasc Res. 34:1997;306-312.
82. Kluge A., Zimmermann R., Munkel B., et al. Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res. 29:1995;407-415.
83. Kluge A., Zimmermann R., Munkel B., Verdouw P.D., Schaper J., Schaper W. Insulin-like growth factor II is an experimental stress inducible gene in a porcine model of brief coronary occlusions. Cardiovasc Res. 29:1995;708-716.
84. Froesch E.R., Schmid C., Schwander J., Zapf J. Actions of insulin-like growth factors. Annu Rev Physiol. 47:1985;443-467.
85. Kluge A., Zimmermann R., Weihrauch D., et al. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res. 33:1997;324-331.
86. Goad D.L., Rubin J., Wang H., Tashjian A.H. Jr., Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology. 137:1996;2262-2268.
87. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 187:1992;1579-1586.
88. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
89. Lee J., Gray A., Yuan J., Luoh S.M., Avraham H., Wood W.I. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA. 93:1996;1988-1992.
90. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 122:1996;3829-3837.
91. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;290-298.
92. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
93. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
94. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 269:1994;26988-26995.
95. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 270:1996;H1803-1811.
96. Sellke F.W., Wang S.Y., Stamler A., Lopez J.J., Li J., Simons M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 271:1996;H713-720.
97. Shen H., Clauss M., Ryan J., et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood. 81:1993;2767-2773.
98. Sharma H.S., Wunsch M., Brand T., Verdouw P.D., Schaper W. Molecular biology of the coronary vascular and myocardial responses to ischemia. J Cardiovasc Pharmacol. 20:(Suppl 1):1992;S23-31.
99. Tuder R.M., Flook B.E., Voelkel N.F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 95:1995;1798-1807.
100. Brogi E., Schatteman G., Wu T., et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest. 97:1996;469-476.
101. Waltenberger J., Mayr U., Pentz S., Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 94:1996;1647-1654.
102. Knoepfler P.S., Bloor C.M., Carroll S.M. Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. J Mol Cell Cardiol. 27:1995;1317-1324.
103. Tyagi S.C., Kumar S., Cassatt S., Parker J.L. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Can J Physiol Pharmacol. 74:1996;983-995.
104. Wang H., Keiser J.A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells. Circ Res. 83:1998;832-840.
105. Falcone D.J., McCaffrey T.A., Haimovitz-Friedman A., Vergilio J.A., Nicholson A.C. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 268:1993;11951-11958.
106. Saksela O., Rifkin D.B. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol. 110:1990;767-775.
107. Pepper M.S., Sappino A.P., Stocklin R., Montesano R., Orci L., Vassalli J.D. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 122:1993;673-684.
108. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci. 110:1997;2293-2302.
109. Banai S., Jaklitsch M.T., Casscells W., et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res. 69:1991;76-85.
110. Unger E.F., Banai S., Shou M., et al. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res. 27:1993;785-791.
111. Unger E.F., Shou M., Sheffield C.D., Hodge E., Jaye M., Epstein S.E. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am J Physiol. 264:1993;H1567-1574.
112. Yanagisawa-Miwa A., Uchida Y., Nakamura F., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 257:1992;1401-1403.
113. Battler A., Scheinowitz M., Bor A., Hasdai D., et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol. 22:1993;2001-2006.
114. Shou M., Thirumurti V., Rajanayagam S., et al. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J Am Coll Cardiol. 29:1997;1102-1106.
115. Unger E.F., Banai S., Shou M., et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol. 266:1994;H1588-1595.
116. Lazarous D.F., Scheinowitz M., Shou M., et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation. 91:1995;145-153.
117. Harada K., Grossman W., Friedman M., et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest. 94:1994;623-630.
118. Lopez J.J., Edelman E.R., Stamler A., et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther. 282:1997;385-390.
119. Lopez J.J., Edelman E.R., Stamler A., et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol. 274:1998;H930-936.
120. Uchida Y., Yanagisawa-Miwa A., Nakamura F., et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J. 130:1995;1182-1188.
121. Landau C., Jacobs A.K., Haudenschild C.C. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am Heart J. 129:1995;924-931.
122. Lazarous D.F., Shou M., Stiber J.A., et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res. 36:1997;78-85.
123. Banai S., Jaklitsch M.T., Shou M., et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 89:1994;2183-2189.
124. Pearlman J.D., Hibberd M.G., Chuang M.L., et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Med. 1:1995;1085-1089.
125. Harada K., Friedman M., Lopez J.J., et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 270:1996;H1791-1802.
126. Lazarous D.F., Shou M., Scheinowitz M., et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
127. Giordano F.J., Ping P., McKirnan M.D., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med. 2:1996;534-539.
128. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 97:1998;645-650.
129. Sellke F.W., Laham R.J., Edelman E.R., Pearlman J.D., Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 65:1998;1540-1544.
130. Hariawala M.D., Horowitz J.R., Esakof D., et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 63:1996;77-82.
131. Lopez J.J., Laham R.J., Carrozza J.P., et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol. 273:1997;H1317-1323.
132. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 265:1993;H586-592.
133. Hood J.D., Meininger C.J., Ziche M., Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 274:1998;H1054-1058.
134. Sellke F.W., Wang S.Y., Friedman M., et al. Beta-adrenergic modulation of the collateral-dependent coronary microcirculation. J Surg Res. 59:1995;185-190.
135. Sellke F.W., Li J., Stamler A., Lopez J.J., Thomas K.A., Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 120:1996;182-188.
136. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 100:1997;3131-3139.
137. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 101:1998;2567-2578.
138. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 99:1997;2625-2634.
139. Morbidelli L., Chang C.H., Douglas J.G., Granger H.J., Ledda F., Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol. 270:1996;H411-415.
140. Pipili-Synetos E., Sakkoula E., Haralabopoulos G., Andriopoulou P., Peristeris P., Maragoudakis M.E. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol. 111:1994;894-902.
141. Sarkar R., Webb R.C. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J Vasc Res. 35:1998;135-142.
142. Babaei S., Teichert-Kuliszewska K., Monge J.C., Mohamed F., Bendeck M.P., Stewart D.J. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res. 82:1998;1007-1015.
143. Ziche M., Parenti A., Ledda F., et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res. 80:1997;845-852.
144. Metais C., Li J., Li J., Simons M., Sellke F.W. Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol. 275:1998;H1411-H1418.
145. Yarom R., Zirkin H., Stammler G., Rose A.G. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol. 166:1992;265-270.
146. Rivard A., Silver M., Fabre J.-E., Magner M., Kearney M., Isner J.M. Diabetes impairs angiogenesis in limb ischemia. Circulation. 96:1997;I-175.
147. Geiger M., Binder B.R. Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors. J Biol Chem. 259:1984;2976-2981.
148. Zhuang H.X., Wuarin L., Fei Z.J., Ishii D.N. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther. 283:1997;366-374.
149. Bitar M.S., Pilcher C.W., Khan I., Waldbillig R.J. Diabetes-induced suppression of IGF-1 and its receptor mRNA levels in rat superior cervical ganglia. Diabetes Res Clin Pract. 38:1997;73-80.